Cures Acceleration Network Review Board
Authorized to reduce significant barriers to successful translation and accelerate the development of high-need cures, the Cures Acceleration Network (CAN) provides NCATS with flexibility in how it funds projects. This authority is guided by the CAN Review Board, which according to its charter, advises and provides recommendations to the NCATS director on the policies, programs and procedures for carrying out the duties of the Office of the Director and on identifying significant barriers to successful translation of basic science into clinical application.
The Board is comprised of 24 members who are appointed by the Secretary of the U.S. Department of Health and Human Services. Members serve four-year terms. Ex-officio members from NIH, the Office of the Assistant Secretary of Defense for Health Affairs, the Office of the Under Secretary for Health for the Department of Veterans Affairs, the National Science Foundation, and the U.S. Food and Drug Administration also are appointed and serve three-year terms.
The CAN Review Board meets four times each year. View the schedule below for upcoming meetings; past meeting minutes, agendas and videocasts also are available.
IOM Workshop on CAN
As requested by Congress, NCATS contracted with the Institute of Medicine (IOM) to host a two-day workshop to discuss the authorities provided to NCATS by the recently authorized Cures Acceleration Network (CAN). “Maximizing the Goals of the Cures Acceleration Network to Accelerate the Development of New Drugs and Diagnostics: A Workshop” was held on June 4-5, 2012.
On Jan. 23, 2013, NCATS Director Christopher P. Austin, M.D., led his first meeting of the NCATS Advisory Council and Cures Acceleration Network Review Board.